Q-omics provides the consensus-scored MC3R profile across patient tissues and cancer cell-line models. MC3R expression is associated with patient survival in 16 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, MC3R is differentially expressed in 4, with the highest sampling consensus in STAD. Additionally, MC3R RNA expression shows 6,268 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight BLCA, and STAD as cancer lineages where MC3R shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MC3R — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MC3R survival associations across molecular data types. MC3R RNA expression shows survival associations in the most cancer types (16), followed by mutation status (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MC3R RNA expression–survival associations across cancer types. High MC3R expression shows unfavorable associations in BLCA, KIRC, STAD, DLBC, SARC and LIHC. The BLCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify BLCA as the clearest survival context for MC3R RNA expression.
This table summarizes MC3R tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in STAD for RNA.
This table ranks reproducible tumor–normal expression differences for MC3R. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MC3R shows higher tumor expression in STAD, UCEC, COAD and LUSC. The STAD box plot shows higher MC3R RNA expression in tumor versus normal tissue (log2 FC = +0.021, t-test p = .005).
This table shows molecular features associated with MC3R in patient tissues and cancer cell lines. In patient samples, MC3R shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set. In cancer cell lines, MC3R RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and LARGE_INTESTINE.
